HER2 (ERBB2)-mutant mNSCLC 1L treatment discussion

Meeting Host

Description

When

November 3, 2026 | 6:00-7:00 pm EST

Where

Webinar - Login information will be sent to all registered attendees 24 hours in advance of the airing date.

Meeting Description

Boehringer Ingelheim invites you to join us at 6:00-7:00 pm EST on Tuesday, November 3rd for a discussion about a first-line treatment option for adult patients with HER2 (ERBB2)-mutant metastatic non-small cell lungcancer (mNSCLC). The following experts will host this engaging online presentation:

• Isabel Preeshagul, DO, MS
  Associate Attending Physician
  Memorial Sloan KetteringCancer Center
• Joshua Sabari, MD
  Associate Professor
  NYU Grossman School of Medicine
  NYU Langone Health
• Beth Sandy, CRNP, MSN
  Thoracic OncologyAbramson Cancer Center
  University of Pennsylvania

Registration

Please email laura.kupcunas@boehringer-ingelheim.com if you would like to participate in this special event. You can also visit www.UpdateHER2.com to learn more about the role of HER2 (ERBB2) mutations as actionable drivers in NSCLC and related unmet needs. Thank you for your interest.